2055362-74-6
2055362-74-6 結(jié)構(gòu)式
基本信息
ADH 503
ADH-503
ADH-503
ADH503
ADH 503
ADH-503 - Leukadherin-1 choline salt
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-15701B | ADH-503;ADH503;ADH 503 ADH-503 | 2055362-74-6 | 1 mg | 245元 |
| 2026/06/05 | HY-15701B | ADH-503;ADH503;ADH 503 ADH-503 | 2055362-74-6 | 5mg | 550元 |
| 2026/06/05 | HY-15701B | ADH-503;ADH503;ADH 503 ADH-503 | 2055362-74-6 | 10mM * 1mLin DMSO | 635元 |
常見問題列表
CD11b
ADH-503 ((Z)-Leukadherin-1 choline; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b + cells and subsets of CD11b + monocytes, granulocytes, eosinophils, and macrophages.
ADH-503 ((Z)-Leukadherin-1 choline; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
ADH-503 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC
0-t
in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively.
| Animal Model: | KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras G12D /p53 flox/flox ] |
| Dosage: | 30, 60, or 120 mg/kg |
| Administration: | Oral gavage; 60 days |
| Result: | Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. |
| Animal Model: | Male rats |
| Dosage: | 30, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral gavage twice a day; on days 1 and 5 |
| Result: | Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC 0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively. |